To investigate the potential impact of IHCH9033 treatment on AML patients, we executed comparable gene expression analysis of these class I HDAC members between AML tumor and normal tissues, revealing that HDAC1, HDAC2 and HDAC3 were notably overexpressed in AML (Fig. 3f). This evidence concerns the gene HDAC3 and acute myeloid leukemia.